Why We're Passionate
Commitment to Humanity
Atherosclerosis is the leading cause of mortality in the USA and globally. Statins are a current standard of care in longevity pharma, but they only attempt to prevent plaque formation, and the numbers don't lie. One in every five deaths are still cardiac-related, and this fact is unacceptable. Unlike interventions that seek to prevent future plaques, we're targeting the root cause with our longbio approach and aiming to clear existing plaques that have already formed. Our innovative strategy could be likened to a senolytic vaccine, offering a vaccination against aging by focusing on removing the underlying issues.
Groundbreaking Innovation
At longbio, we utilize a novel vaccine platform known as a virus-like particle to specifically target a cell type that contributes to the aging process. Scientific research has established a connection between this cell type and plaque formation, and the clearance of these plaques has demonstrated remarkable benefits. Our preclinical findings indicate that our senolytic vaccine exhibits double the efficacy of the best statins currently available in the longevity pharma market. Additionally, our upcoming studies will confirm whether this vaccination against aging can effectively clear existing plaques, potentially showcasing a true cure. Once these data are validated, we will have a clear pathway towards initiating clinical trials.
The Power of Targeting Aging
Outside of atherosclerosis, we have observed therapeutic benefits across every organ system monitored, showcasing the potential of longevity biotech. These include pulmonary protections, hair loss reductions, prolapse prevention, and even lifespan extension. Imagine the diseases that can be mitigated from targeting the aging process itself, a principle at the heart of longbio research and longevity pharma. This is the power derived from a senolytic vaccine and the concept of vaccination against aging, focusing on a fundamental driver of human aging.
A Vaccine for All Who Desire It
Financial projections position this senolytic vaccine as cost-competitive with statins, while also offering multi-morbidity intervention capabilities. As we scale, we anticipate further cost reductions for the consumer. Our longevity biotech platform can be manufactured in a thermostable manner, facilitating global expansion into even the most remote areas of the Earth. We are on a mission to provide everyone with a choice in vaccination against aging, regardless of socioeconomic status or geopolitical position, in line with the goals of longevity pharma.
Contact Us
